FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Drug Test Anal / Pharmacokinetics and effects on arachidonic acid metabolism ...
Drug testing and analysis2021; 13(7); 1305-1317; doi: 10.1002/dta.3028

Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses.

Abstract: The increasing availability of cannabidiol (CBD) and anecdotal reports of its anti-inflammatory effects has garnered it much interest in the equine industry. The objectives of the current study were to (1) describe the pharmacokinetics of oral CBD in exercising thoroughbreds, (2) characterize select behavioral and physiologic effects, and (3) evaluate effects on biomarkers of inflammation using an ex vivo model. This study was conducted in a randomized balanced 3-way crossover design with a two-week washout period between doses. Horses received a single oral dose (0.5, 1, and 2 mg/kg) of CBD suspended in sesame oil. Blood and urine samples were collected prior to and for 72 hr post drug administration. Additional blood samples collected at select time points were challenged ex vivo with calcium ionophore or lipopolysaccharide to induce eicosanoid production. Drug, metabolite, and eicosanoid concentrations were determined using LC-MS/MS. Cannabidiol was well tolerated with no significant behavioral, gastrointestinal, or cardiac abnormalities observed. CBD was readily absorbed, with parent drug detected in blood at all time points. The carboxylated and hydroxylated metabolites predominated in serum and urine, respectively. The terminal half-life for CBD was 10.7 ± 3.61, 10.6 ± 3.84 and 9.88 ± 3.53 for 0.5, 1, and 2 mg/kg. Although the effects were mixed, results of eicosanoid analysis suggest CBD affects COX-1, COX-2 and LOX at the doses studied here. Results of this study coupled with previous reports in other species, suggest further study of CBD in horses is warranted before its use as an anti-inflammatory can be recommended.
© 2021 John Wiley & Sons, Ltd.
Get Full Text
Publication Date: 2021-03-31 PubMed ID: 33723919DOI: 10.1002/dta.3028Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article
  • Randomized Controlled Trial
  • Veterinary

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article explores the effects of oral administration of cannabidiol (CBD) on horses, specifically its pharmacokinetics, behavioral and physiological effects, and its potential anti-inflammatory properties. CBD, a compound derived from cannabis, was tested on thoroughbreds in low doses and was found to interact with certain enzymes connected to inflammation, suggesting that further research would be beneficial to explore its potential as an anti-inflammatory treatment for horses.

Research Design and Methodology

  • This study was conducted using a randomized balanced 3-way crossover design with a two-week washout period between doses. This means the same group of horses received different treatments over distinct periods, with a sufficient ‘washout’ period to ensure the effect of the previous treatment does not impact the results of the following one.
  • The horses were administered three different doses of CBD (0.5, 1, and 2 mg/kg) orally suspended in sesame oil.
  • Before and for 72 hours after the administration of CBD, blood and urine samples were collected from the horses to monitor CBD concentrations.
  • Further blood samples were taken at select times and subsequently stimulated ex vivo – outside the living body – with calcium ionophore or lipopolysaccharide. This was to induce the production of eicosanoids, molecules that are part of the mediators of inflammation, allowing researchers to evaluate the inflammatory response.
  • Using LC-MS/MS, a type of mass spectrometry, investigators were of interest in drug concentrations, metabolite concentrations (what the CBD was broken down into), and eicosanoid levels.

Findings

  • The study found that CBD was well-tolerated in low doses by the horses, producing no significant cardiac, behavioral, or gastrointestinal complications.
  • CBD was readily absorbed, with the parent drug detected in the blood at all times after dosing. Different types of metabolites were predominantly found in the serum and urine samples.
  • The half-life of CBD – the time it took for the body to eliminate half the dosage – was determined to be around 10 hours for all three administered doses.
  • Although mixed, the results showed that CBD has an effect on COX-1, COX-2 and LOX enzymes, all of which are implicated in the inflammation process. These results suggest that CBD might possess anti-inflammatory properties.

Implications

  • This study provided interesting findings about CBD and its potential anti-inflammatory properties in horses. However, the authors highlighted that the results were mixed,
  • Recommendation of CBD as an anti-inflammatory can only be made after further research on CBD use in horses have been conducted since the present study’s results were inconclusive.

Cite This Article

APA
Ryan D, McKemie DS, Kass PH, Puschner B, Knych HK. (2021). Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses. Drug Test Anal, 13(7), 1305-1317. https://doi.org/10.1002/dta.3028

Publication

Drug testing and analysis
ISSN: 1942-7611
NlmUniqueID: 101483449
Country: England
Language: English
Volume: 13
Issue: 7
Pages: 1305-1317

Researcher Affiliations

Ryan, Declan
  • K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, California, USA.
McKemie, Dan S
  • K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, California, USA.
Kass, Philip H
  • Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, California, USA.
Puschner, Birgit
  • School of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Knych, Heather K
  • K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, California, USA.
  • Department of Veterinary Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California, USA.

MeSH Terms

  • Administration, Oral
  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / pharmacology
  • Arachidonic Acid / metabolism
  • Biomarkers / metabolism
  • Cannabidiol / administration & dosage
  • Cannabidiol / pharmacokinetics
  • Cannabidiol / pharmacology
  • Chromatography, Liquid
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Half-Life
  • Horses
  • Inflammation / drug therapy
  • Inflammation / veterinary
  • Tandem Mass Spectrometry

Grant Funding

  • California Department of Food and Agriculture Equine Medication Monitoring Program
  • California Horse Racing Board

References

This article includes 45 references
  1. https://apnews.com/press-release/pr-newmediawire/afd4a5b001af1f1f03b2f8b3a732fd1e No Title.
  2. Silver R. The endocannabinoid system of animals. Anim Open Access J MDPI 2019;9.
  3. Nakajima Y, Furuichi Y, Biswas KK. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-κB pathway inhibition. FEBS Lett 2006;580:613-619.
  4. Ludtke DD, Siteneski A, Galassi T d O. High-intensity swimming exercise reduces inflammatory pain in mice by activation of the endocannabinoid system. Scand J Med Sci Sports 2020;30:1369-1378.
  5. Jamshidi N, Taylor D. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001;134:1151-1154.
  6. Hartmann A, Fassini A, Scopinho A. Role of the endocannabinoid system in the dorsal hippocampus in the cardiovascular changes and delayed anxiety-like effect induced by acute restraint stress in rats. J Psychopharmacol 2019;33:606-614.
  7. Hacke A, Lima D, de Costa F. Probing the antioxidant activity of Δ 9-tetrahydrocannabinol and cannabidiol in Cannabis sativa extracts. Analyst 2019;144:4952-4961.
  8. Costa B, Colleoni M, Conti S. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 2004;369:294-299.
  9. Evans A, Formukong E, Evans F. Actions of cannabis constituents on enzymes of arachidonate metabolism: anti-inflammatory potential. Biochem Pharmacol 1987;36:2035-2037.
  10. Beretta C, Garavaglia G, Cavalli M. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res 2005;52:302-306.
  11. Brideau C, Van Staden C, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res 2001;62:1755-1760.
  12. Galbraith E, McKellar Q. Protein binding and in vitro serum thromboxane B2 inhibition by flunixin meglumine and meclofenamic acid in dog, Goat and Horse Blood. Res Vet Sci 1996;61:78-81.
  13. Knych HK, Arthur RM, Mckemie DS, Chapman N. Pharmacokinetics and effects on thromboxane B2 production following intravenous administration of flunixin meglumine to exercised thoroughbred horses. J Vet Pharmacol Ther 2015;38:313-320.
  14. Lees P, McKellar Q, May SA, Ludwig B. Pharmacodynamics and pharmacokinetics of carprofen in the horse. Equine Vet J 1994;26:203-208.
  15. Lees P, Ewins CP, Taylor JB, Sedgwick AD. Serum thromboxane in the horse and its inhibition by aspirin, Phenylbutazone and Flunixin. Br Vet J 1987;143:462-476.
  16. Mangal D, Uboh CE, Soma LR. Analysis of bioactive eicosanoids in equine plasma by stable isotope dilution reversed-phase liquid chromatography/multiple reaction monitoring mass spectrometry. Rapid Commun Mass Spectrom 2011;25:585-598.
  17. Mangal D, Uboh CE, Soma LR, Liu Y. Inhibitory effect of triamcinolone acetonide on synthesis of inflammatory mediators in the equine. Eur J Pharmacol 2014;736:1-9.
  18. Knych HK, Arthur RM, Mitchell MM. Pharmacokinetics and selected pharmacodynamics of cobalt following a single intravenous administration to horses. Drug Test Anal 2015;7:619-625.
  19. Hamamoto-Hardman BD, Steffey EP, Weiner D, McKemie DS, Kass P, Knych HK. Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses. J Vet Pharmacol Ther 2019;401-410.
  20. Knych HK, Arthur RM, McKemie DS, Baden R, Oldberg N, Kass PH. Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. Equine Vet J 2019;51:238-245.
  21. Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos 1988;16:469-472.
  22. Millar SA, Stone NL, Yates AS, O'Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol 2018;9:1365.
  23. Perucca W, Bialer M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, And Related Clinical Implications. CNS Drugs 2020;34:795-800.
  24. Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A Phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 2018;32:1053-1067.
  25. Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia 2020;61:267-277.
  26. Dyke T, Hubbell J, Sams R, Hinchcliff K. Hepatic blood flow in horses during the recuperative period from maximal exercise. Am J Vet Res 1998;59:1476-1480.
  27. Harvey D, Samara E, Mechoulam R. Comparative metabolism of cannabidiol in dog, Rat and Man. Pharmacol Biochem Behav 1991;40:523-532.
  28. Wakshlag JJ, Schwark WS, Deabold KA. Pharmacokinetics of cannabidiol, cannabidiolic acid, δ9-tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract. Front Vet Sci 2020;7:505.
  29. Guy GW, Flint ME. A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of Cannabis Based Medicine Extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT). J Cannabis Ther 2004;3:35-77.
  30. Guy GW, Robson PJ. A Phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a Cannabis Based Medicine Extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of cbme per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther 2004;3:79-120.
  31. Atsmon J, Cherniakov I, Izgelov D. PTL401, a new formulation based on pro-nano dispersion technology, improves oral cannabinoids bioavailability in healthy volunteers. J Pharm Sci 2018;107:1423-1429.
  32. Atsmon J, Heffetz D, Deutsch L, Deutsch F, Sacks H. Single-dose pharmacokinetics of oral cannabidiol following administration of PTL101: a new formulation based on gelatin matrix pellets technology. Clin Pharmacol Drug Dev 2018;7:751-758.
  33. Zuardi A, Sl M, Guimaraes F, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995;56:485-486.
  34. Zuardi A, Crippa J, Dursun S. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol 2010;24:135-137.
  35. Fairbairn J, Pickens J. The oral activit of delta-9-tetrahydrocannabinol and its dependence on prostaglandin E2. Br J Pharmacol 1979;67:379-385.
  36. Vaughn D, Kulpa J, Paulionis L. Preliminary investigation of the safety of escalating cannabinoid doses in healthy dogs. Front Vet Sci 2020;7:51.
  37. Hayakawa K, Mishima K, Hazekawa M. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 2008;1188:157-164.
  38. Klein C, Karanges E, Spiro A. Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) 2011;218:443-457.
  39. Reid MJ, Bornheim LM. Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochem Pharmacol 2001;61:1357-1367.
  40. Taffe MA, Creehan KM, Vandewater SA. Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Ù9-tetrahydrocannabinol in Sprague-Dawley rats. Br J Pharmacol 2015;172:1783-1791.
  41. Hollister LE, Gillespie H. Interactions in man of delta-9-tetrahydrocannabinol; II Cannabinol and Cannabidiol. Clin Pharmacol Ther 1975;18:80-83.
  42. White HL, Tansik RL. Effects of delta 9-tetrahydrocannabinol and cannabidiol on phospholipase and other enzymes regulating arachidonate metabolism. Prostaglandins Med 1980;4:409-417.
  43. Young JM, Panah S, Satchawatcharaphong C, Cheung PS. Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and-2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. 1996.
  44. Formukong EA, Evans AT, Evans FJ, Garland LG. Inhibition of A23187-induced release of leukotriene B4 in mouse whole blood Ex vivo and human polymorphonuclear cells in vitro by the cannabinoid analgesic cannabidiol. Phyther Res 1991;5:258-261.
  45. Barrett ML, Gordon D, Evans FJ. Isolation from cannabis sativa L. of cannflavin-a novel inhibitor of prostaglandin production. Biochem Pharmacol 1985;34:2019-2024.

Citations

This article has been cited 21 times.
  1. Eichler F, Poźniak B, Machnik M, Schenk I, Wingender A, Baudisch N, Thevis M, Bäumer W, Lischer C, Ehrle A. Pharmacokinetic modelling of orally administered cannabidiol and implications for medication control in horses. Front Vet Sci 2023;10:1234551.
    doi: 10.3389/fvets.2023.1234551pubmed: 37621871google scholar: lookup
  2. Mercer MA, Davis JL, McKenzie HC. The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses. Animals (Basel) 2023 May 10;13(10).
    doi: 10.3390/ani13101597pubmed: 37238029google scholar: lookup
  3. Leise JM, Leatherwood JL, Paris BL, Walter KW, George JM, Martinez RE, Glass KP, Lo CP, Mays TP, Wickersham TA. Evaluation of an Oral Supplemental Cannabidiol Product for Acceptability and Performance in Mature Horses. Animals (Basel) 2023 Jan 10;13(2).
    doi: 10.3390/ani13020245pubmed: 36670785google scholar: lookup
  4. Tou K, Cawley A, Bowen C, Bishop DP, Fu S. Towards Non-Targeted Screening of Lipid Biomarkers for Improved Equine Anti-Doping. Molecules 2022 Dec 30;28(1).
    doi: 10.3390/molecules28010312pubmed: 36615506google scholar: lookup
  5. Kwee CM, van Gerven JM, Bongaerts FL, Cath DC, Jacobs G, Baas JM, Groenink L. Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool. J Psychopharmacol 2022 Dec;36(12):1299-1314.
    doi: 10.1177/02698811221124792pubmed: 36239014google scholar: lookup
  6. Galiazzo G, De Silva M, Giancola F, Rinnovati R, Peli A, Chiocchetti R. Cellular distribution of cannabinoid-related receptors TRPV1, PPAR-gamma, GPR55 and GPR3 in the equine cervical dorsal root ganglia. Equine Vet J 2021 Aug 21;54(4):788-98.
    doi: 10.1111/evj.13499pubmed: 34418142google scholar: lookup
  7. Shilo-Benjamini Y, Milgram J, Lavy E, Quint M, Barasch D, Cern A, Barenholz Y. Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial. Front Vet Sci 2025;12:1746266.
    doi: 10.3389/fvets.2025.1746266pubmed: 41635790google scholar: lookup
  8. Ekstrand C, Michanek P, Hernlund E, Gehring R, Spjut K, Salomonsson M. Differences in Plasma Exposure of Cannabidiol and Cannabidiolic Acid Following Oral Administration to Horses. J Vet Pharmacol Ther 2026 Jan;49(1):22-32.
    doi: 10.1111/jvp.70027pubmed: 41017237google scholar: lookup
  9. Wermer K, Korbacska-Kutasi O, Berkecz R, Csupor D, Ágh N, Sztojkov-Ivanov A, Cserhalmi D. Pharmacokinetics of cannabidiol and its two main phase I metabolites in Connemara ponies. Front Vet Sci 2025;12:1599934.
    doi: 10.3389/fvets.2025.1599934pubmed: 40654508google scholar: lookup
  10. Bazzano M, Laus F, Cerquetella M, Spaterna A, Marchegiani A. Effect of orally administered cannabidiol oil on daily tonometric curve in healthy Italian Saddle horses. PLoS One 2025;20(5):e0325191.
    doi: 10.1371/journal.pone.0325191pubmed: 40435047google scholar: lookup
  11. Kitts-Morgan SE, Sams RA, Muir WW. Pharmacokinetics of cannabidiol, (-)-trans-Δ(9)-tetrahydrocannabinol, and their oxidative metabolites after intravenous and oral administration of a cannabidiol-dominant full-spectrum hemp product to beagle dogs. Front Vet Sci 2025;12:1556975.
    doi: 10.3389/fvets.2025.1556975pubmed: 40264990google scholar: lookup
  12. Di Salvo A, Bazzano M, Rocca GD, Galarini R, Marchegiani A, Paoletti F, Giusepponi D, Mantovani M, Laus F. Pharmacokinetics of a single oral administration of two cannabidiol formulations in fed and fasted horses. Front Vet Sci 2025;12:1515833.
    doi: 10.3389/fvets.2025.1515833pubmed: 40046423google scholar: lookup
  13. Aragona F, Tabbì M, Gugliandolo E, Giannetto C, D'Angelo F, Fazio F, Interlandi C. Role of cannabidiolic acid or the combination of cannabigerol/cannabidiol in pain modulation and welfare improvement in horses with chronic osteoarthritis. Front Vet Sci 2024;11:1496473.
    doi: 10.3389/fvets.2024.1496473pubmed: 39720409google scholar: lookup
  14. Pinto K, Requicha JF. Cannabis sativa in veterinary medicine: Foundations and therapeutic applications. Can Vet J 2024 Sep;65(9):948-958.
    pubmed: 39219599
  15. Di Salvo A, Chiaradia E, Sforna M, Della Rocca G. Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review. Vet Res Commun 2024 Oct;48(5):2915-2941.
    doi: 10.1007/s11259-024-10509-7pubmed: 39162768google scholar: lookup
  16. Thomson ACS, McCarrel TM, Zakharov A, Gomez B, Lyubimov A, Schwark WS, Mallicote MF, Portela DA, Bisiau AL, Wakshlag JJ. Pharmacokinetics and tolerability of single-dose enteral cannabidiol and cannabidiolic acid rich hemp in horses (Equus caballus). Front Vet Sci 2024;11:1356463.
    doi: 10.3389/fvets.2024.1356463pubmed: 38681854google scholar: lookup
  17. Interlandi C, Tabbì M, Di Pietro S, D'Angelo F, Costa GL, Arfuso F, Giudice E, Licata P, Macrì D, Crupi R, Gugliandolo E. Improved quality of life and pain relief in mature horses with osteoarthritis after oral transmucosal cannabidiol oil administration as part of an analgesic regimen. Front Vet Sci 2024;11:1341396.
    doi: 10.3389/fvets.2024.1341396pubmed: 38379920google scholar: lookup
  18. Eichler F, Ehrle A, Machnik M, Jensen KC, Wagner S, Baudisch N, Bolk J, Pötzsch M, Thevis M, Bäumer W, Lischer C, Wiegard M. Behavioral observations, heart rate and cortisol monitoring in horses following multiple oral administrations of a cannabidiol containing paste (part 2/2). Front Vet Sci 2023;10:1305873.
    doi: 10.3389/fvets.2023.1305873pubmed: 38234983google scholar: lookup
  19. Eichler F, Ehrle A, Jensen KC, Baudisch N, Petersen H, Bäumer W, Lischer C, Wiegard M. Behavioral observations, heart rate and heart rate variability in horses following oral administration of a cannabidiol containing paste in three escalating doses (part 1/2). Front Vet Sci 2023;10:1305868.
    doi: 10.3389/fvets.2023.1305868pubmed: 38149295google scholar: lookup
  20. Johns TN, Wakshlag JJ, Lyubimov AV, Zakharov A, Burnside WM. Pharmacokinetics of cannabidiol-/cannabidiolic acid-rich hemp oil in juvenile cynomolgus macaques (Macaca fascicularis). Front Vet Sci 2023;10:1286158.
    doi: 10.3389/fvets.2023.1286158pubmed: 38094499google scholar: lookup
  21. Spittler AP, Helbling JE, McGrath S, Gustafson DL, Santangelo KS, Sadar MJ. Plasma and joint tissue pharmacokinetics of two doses of oral cannabidiol oil in guinea pigs (Cavia porcellus). J Vet Pharmacol Ther 2021 Nov;44(6):967-974.
    doi: 10.1111/jvp.13026pubmed: 34658021google scholar: lookup
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.